Q2 2024 Brainsway Ltd Earnings Call Transcript
Key Points
- BrainsWay Ltd (BRSYF) reported a 28% year-over-year increase in revenues, reaching $10 million for the second quarter of 2024.
- The company achieved positive quarterly net income for the third consecutive quarter and positive adjusted EBITDA and cash flow from operations for the fourth consecutive quarter.
- BrainsWay Ltd (BRSYF) has a strong balance sheet with $48.1 million in cash and no debt as of June 30, 2024.
- The company expanded its international footprint, including a new multi-year distribution agreement in Canada, enhancing market entry and growth potential.
- The FDA granted an expanded indication for Deep TMS treatment of major depressive disorder for patients aged 22 to 86, making it the first TMS indicated for patients over 68, which could significantly increase the target market.
- Operating expenses remain a concern, with general and administrative expenses increasing to $1.4 million from $1.2 million in the same quarter of the previous year.
- Despite international expansion, 80% of the installed base remains domestic, indicating potential over-reliance on the US market.
- The Canadian distribution agreement systems are not yet active, with delivery and activation expected by the end of the year, which may delay revenue realization.
- The company is still in discussions for distribution channels for its addiction treatment, indicating potential delays in market entry for this segment.
- The company faces challenges in accelerating market penetration for its MDD indication, particularly in the elderly patient segment, which requires targeted strategies and partnerships.
Good day and welcome to the BrainsWay second quarter 2024 earnings conference call. (Operator Instructions). Please note this event is being recorded.
I would now like to turn the conference over to Brian Ritchie of LifeSci Advisors. Please go ahead.
Thank you all, and welcome to BrainsWay's second quarter 2024 earnings conference call. With us today are BrainsWay's Chief Executive Officer, Hadar Levy; and Chief Financial Officer, Ido Marom. The format for today's call will be a discussion of recent trends and business updates from Hadar, followed by a detailed discussion of the financials. Then, we will open up the call for your questions. Earlier today, BrainsWay released financial results for the three and six months ended June 30, 2024. A copy of the press release is available on the company's Investor Relations website.
Before I turn the call over to Hadar, I would like to remind you that this conference call, including both management's prepared remarks and the question-and-answer session, may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
